

February 19, 2026
 SymBio Pharmaceuticals Limited
 Fuminori Yoshida
 Representative Director
 President and Chief Executive Officer
 (Securities Code: 4582)

Notification of Amendment to the Articles of Incorporation

SymBio Pharmaceuticals Limited (the “Company”) today announced that, pursuant to the resolution passed by the Company’s Board of Directors today, a proposal regarding Amendment of the Articles of Incorporation will be submitted to the 21st Annual General Meeting of Shareholders scheduled to be held on March 24, 2026.

1. Reasons for the proposal

As of December 31, 2025, a total of 59,567,080 shares of the Company had been issued out of a total of 115,000,000 authorized shares. To enable flexible fundraising in preparation for future business expansion, we propose to increase the total number of authorized shares.

2. Proposed amendment

The details of the proposed amendment are as follows:

Current Articles of Incorporation	Proposed Change
Article 6 (Total number of authorized shares) The total number of authorized shares of the Company shall be <u>115,000,000</u> .	Article 6 (Total number of authorized shares) The total number of authorized shares of the Company shall be <u>235,000,000</u> .

3. Purpose of the change

Currently, the Company is conducting a global Phase 3 clinical trial targeting adenovirus infection after hematopoietic stem cell transplantation, with 80 sites in Europe and the United States serving as the initial sites, and has furthermore initiated a Phase 2 clinical trial for progressive multifocal leukoencephalopathy (PML), bringing the total to two late-stage clinical trials.

In addition, in the oncology field, the Company is making preparations to initiate clinical trials. The Company has designated viral infections, cancer, and neurodegenerative diseases as its core business domains and, in addition to the clinical trials currently underway, will pursue a pipeline strategy targeting multiple diseases.

Furthermore, when a promising candidate following brincidofovir emerges, the Company will actively

pursue in-licensing of new candidates and advance a pipeline strategy that contributes to its growth strategy. Meanwhile, we are determined to make a major leap forward by further strengthening our global development structure and advancing investments in commercialization infrastructure to build a highly profitable structure from 2030 onward.

The proposed amendment to the Articles of Incorporation will increase the total number of authorized shares of the Company from 115 million to 235 million in order to enable the agile and flexible execution of its capital policy, with a view to ensuring the steady growth of its global business.

[Contact] Investor Relations: Tel: +81 (0)3 5472 1125